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Resumo
As reações agudas de hipersensibilidade a 
meios de contraste (RAHC) em imagiologia são 
consideradas pouco frequentes; são habitualmente 
ligeiras, mas podem ser potencialmente fatais. 
Apesar de existirem recomendações nacionais 
e internacionais sobre a sua abordagem, não 
existe um protocolo clínico que integre a visão de 
todas as especialidades envolvidas (Imagiologia, 
Imunoalergologia e Medicina Intensiva).
Pretendeu-se estabelecer um protocolo prático 
de utilização transversal e adequada à realidade 
hospitalar, que inclua a definição das reações 
adversas e sua classificação, a identificação de 
factores de risco para a ocorrência de reação 
de hipersensibilidade, a abordagem diagnóstica 
e terapêutica e de orientação dos doentes com 
RAHC.
Realizou-se uma revisão não sistemática das 
recomendações nacionais e internacionais 
acerca da abordagem das RAHC, publicadas 
pelas sociedades científicas de Imagiologia, 
Imunoalergologia e Medicina Intensiva e o 
protocolo foi elaborado por consenso de peritos 
destas especialidades.
As reações adversas não renais subdividem-se 
em reações quimiotóxicas (relacionadas com 
as características de cada contraste) e reações 
de hipersensibilidade (com envolvimento de 
mediadores imunológicos de forma IgE e não 
IgE mediada); podem ser classificadas em ligeiras, 
moderadas e graves com abordagens terapêuticas 
específicas. Constituem os principais factores 
de risco para a sua ocorrência, a reação prévia 
a meio de contraste e a asma brônquica. A pré-
medicação diminui a probabilidade de ocorrência 
de sintomas, mas não exclui a possibilidade de 
reação grave. Os doentes com suspeita de reação 
de hipersensibilidade devem ser encaminhados 
para a consulta de Imunoalergologia para 
diagnóstico definitivo, orientação para redução de 
risco e escolha de meio de contraste alternativo. 
A inserção de alertas clínicos, assim como a 
notificação deve ser assegurada.
Este protocolo clínico de consenso de peritos, 
baseado nas indicações nacionais e internacionais 
atuais, pretende ser uma ferramenta passível de 
utilização na prática clínica aquando da abordagem 
do paciente a realizar exames imagiológicos que 
necessitem de meio de contraste. 
Palavras-chave
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Abstract
Acute hypersensitivity reactions to contrast 
media(AHRC) are infrequent, usually mild 
but potentially fatal. Although there are 
recommendations from Radiology, Intensive 
Care and Allergology fields regarding its 
management, a clinical multidisciplinary protocol 
that integrates these complementary approaches 
is missing.
We aimed to elaborate a protocol that includes 
adverse reactions definition and classification; 
identification of  risk factors and management of  
patients with AHRC.
A non systematic revision of  national and 
international guidelines was made regarding the 
management of  hypersensitivity reactions, in 
order to elaborate a clinical consensus protocol 
to be used in different medical fields (Radiology, 
Allergology and Intensive Care).
Non-renal adverse contrast reactions can be 
classified in chemotoxic (related to contrast 
chemical properties) and hypersensitivity 
reactions (with involvement of  immunological 
mediators IgE and non IgE mediated); and in 
mild, moderate and severe (regarding severity), 
with different therapeutic approaches. Identified 
risk factors are previous contrast media reaction 
and asthma. Pre-medication decreases the 
probability of  symptoms but does not exclude 
the possibility of  a severe reaction. Patients 
suspected of  AHRC should be observed in an 
allergy clinic to confirm the diagnosis and find an 
alternative contrast media. Clinical alert record as 
well as the notification of  reaction to surveillance 
system of  adverse drug reactions should be 
performed.
This clinical expert’s protocol consensus based 
on national and international guidelines aims to 
be a valuable practical tool in the management 
of  patients that need contrast media during a 
radiologic exam. 
Keywords
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*Authors’ note: In this document, and following 
the SEAIC designation proposal7, acute non-
renal adverse reactions, allergic and allergic-
like, are referred to as acute contrast media 
hypersensitivity reactions in imaging.
1. Objectives
• To adress the definition of  acute hypersensitivity reaction 
to contrast media and the differential diagnosis with 
chemotoxic reactions;
• To determine risk factors for acute hypersensitivity 
reactions;
• To establish laboratory procedures to be performed in case 
of  suspected allergic reaction; 
• To standardize criteria for clinical diagnosis and treatment 
of  acute hypersensitivity reactions; and
• To define orientation criteria for the allergology 
appointment.
Delayed adverse reactions (from one hour to several days 
after administration of  contrast media) and nephrotoxic 
reactions are outside the scope of  this protocol.
This protocol should be applied to all patients undergoing 
a radiologic study with administration of  contrast media as 
part of  the best practices associated with the use of  contrast 
media in any radiology department.
Various contrast media and various routes of  administration 
are used in imaging; by the frequency and clinical significance 
of  associated acute adverse reactions, this protocol refers 
only to iodinated contrast media and gadolinium-based ones 
when administered intravenously or intra-arterially.
2. Definitions
An acute non-nefrotoxic adverse reaction to a contrast media 
is a noxious and unintentional reaction that occurs up to one 
hour after the administration of  the contrast media and does 
not result from the nephrotoxic effect.
These reactions can be observed with iodinated contrast 
media in procedures such as Angiography, Urography and 
Computed Tomography and with gadolinium contrast 
agents in Magnetic Resonance Imaging being, however, more 
frequent with iodinated contrast media. In terms of  severity, 
the majority of  reactions are mild, whereas life-threatening 
situations are rare.
Acute non-nephrotoxic adverse reactions may be subdivided 
into chemotoxic reactions and hypersensitivity reactions.
Chemotoxic reactions:
• are related to the chemical properties of  the contrasts 
administered, and generally depend on the dose and on 
the infusion rate;
• are usually transient and self  limited, but can be serious. 
They frequently include heat sensation, flushing, nausea 
and vomiting;
• vagal vase reactions are a less frequent type of  chemotoxic 
reactions characterized by hypotension and bradycardia; 
• cardiovascular adverse effects should also be considered in 
the context of  chemotoxic reactions, such as arrhythmias, 
cardiac contractility depression, hypertensive crisis 
and cardiogenic pulmonary edema. In cases of  severe 
hypotension, loss of  consciousness, cardiorespiratory 
arrest, angina, or seizure may occur. These effects are very 
rare;
• the occurrence of  these reactions does not prevent the 
administration of  contrast media in future imaging studies.
Hypersensitivity reactions:
• are idiosyncratic and unpredictable, and may occur in 
response to administration of  minimal amounts of  
contrast media
• can be allergic, mediated by IgE / T lymphocytes 
or  allergic-like mediated by non-specific mechanisms 
of  release of  vasoactive mediators (direct endothelial 
membrane effect, complement system activation or direct 
formation of  bradykinins). 
3. Classification of  adverse reactions according 
to severity
The AHRC classification can be made according to clinical 
severity, in mild, moderate and severe reactions (Table 1).
In cases of  severe cardiovascular reactions, such as pulmonary 
edema, significant hemodynamic instability and cardio-
respiratory arrest, although these reactions may result from a 
chemotoxic reaction, an allergic etiology may be assumed for 
future treatment and referral of  the patient, especially if  signs 
and symptoms of  skin and mucosa involvement coexist.
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Table 1 - Classification of  adverse reactions according to severity
Hypersensitivity reactions Chemotoxic reactions
Mild
Limited urticaria / pruritus
Limited skin edema
Scratched throat
Nasal congestion
Sneezing / conjunctivitis / 
rhinorrhea
Limited vomiting and nausea
“Flushing” / heat sensation
Transient tremors
Headache / dizziness
Anxiety
Taste alteration
Moderate
Generalized urticaria / pruritus
Diffuse erythema with stable vital 
signs
Facial edema without dyspnea
Wheezing / slight bronchospasm
Vomiting and severe nausea
Hypertensive urgency
Isolated chest pain
Vasovagal reaction (which requires 
treatment and responds to 
treatment)
Severe
Facial or generalized edema with 
dyspnea
Diffuse erythema with 
hypotension
Laryngeal edema with stridor and/
or hypoxia
Wheezing / bronchospasm with 
hypoxia
Non-cardiogenic pulmonary 
edema
Anaphylactic shock
Resistant vasovagal reaction
Arrhythmias
Convulsions
Hypertensive emergency
Cardiogenic pulmonary edema
4. Classification of  contrast media
Iodinated contrast media (ICM) are iodine salts whose 
chemical structure includes a benzene ring with at least 3 
iodine atoms which is responsible for the radio-opacity.
The ICM can be classified according to iodine molecule 
loading (ionic and nonionic), molecular structure 
(monomeric and dimeric) and osmolarity (hyperosmolar, 
low osmolarity and iso-osmolarity). Contrast osmolarity is 
the most frequently associated factor with hypersensitivity 
9reactions and reactions are more frequent with those with 
high osmolarity.
Most ICM are classified as:
- monomeric ionic - have the highest osmolarity, are 
essentially used in extravascular procedures such as 
cystograms;
- dimeric ions - the only example is ioxaglate and is low in 
osmolarity;
- monomeric nonionic - are considered second generation, 
have low osmolarity - examples: iohexol, iopamidol, 
ioversol, iopromide, ioxylan, iomeprol;
- dimeric non-ionic - example: iodixanol - is associated with 
equal or lesser number of  hypersensitivity reactions than 
those of  low osmolarity.
The contrast media used in magnetic resonance are gadolinium 
complexes that can be classified as ionic or nonionic and 
according to their structure in linear or macrocyclic.
5. Prevalence
With low osmolarity ICM, the prevalence of  acute 
hypersensitivity reactions is very low (0.2% to 0.7%) and 
severe reactions are even rarer (0.04%).
With gadolinium-based contrast media the prevalence of  
acute hypersensitivity reactions is much lower than with 
iodinated contrast (ranging from 0.24% to 0.07%), and 
severe allergic reactions are extremely rare (with prevalence 
of  0.01 to 0.001%).
6. Risk factors for hypersensitivity reaction 
Two types of  risk factors can be considered
a) Relative to the contrast media
Reactions are more frequent with high osmolarity contrast 
media, however the prevalence of  serious reactions seems 
to be independent of  the degree of  osmolarity.
b) Regarding the patient
The main risk factors for contrast media hypersensitivity 
reactions are:
• Previous history of  AHRC in an imaging study with 
contrast media administration.
• Unstable asthma
Some authors consider that previous history of  bronchial 
asthma, drug allergy, food allergy, female gender may be 
a relative risk factor, however, these do not prevent the 
administration of  contrast media nor do they determine the 
need for premedication.
It should be noted that the occurrence of  a chemotoxic 
reaction in a previous exam with intravenous contrast media 
is not a risk factor for the occurrence of  hypersensitivity 
reaction, therefore there is no need to pre-medicate these 
patients.
The approach of  the patient submitted to a radiologic study 
with contrast media is explained in Figure 1.
7. Attitudes to be taken in patients with risk 
factors
a) General measures
• There should be reciprocal information and coordination 
between the team of  technicians and nurses, and the 
neuro / radiologist;
* To ICM if  a CT or angiography or urography is indicated; to gadolinium-
based contrast media if  a MRI is indicated.
Anti-H1 ns- antihistamine H1non sedative
Figure 1 - Approach of  the patient who will be examined with contrast 
medium
• The patient should remain in the imaging service, in the 
area of  the CT / MRI, with venous access, for 30 min;
• If  you give an antihistamine with a torpor effect (eg 
clemastine IV) to a patient, he/she should not drive or 
work with machines within 6 hours or as long as the 
symptoms of  drowsiness remain.
b) if  there is a history of  mild hypersensitivity reaction
• The examination must be performed;
• Intravenous contrast can be performed, if  important for 
the diagnosis;
• If  the CM to be administered is identical to that associated 
with previous adverse reaction, consider non-sedating 
antihistamine 30 minutes before the test (Tables 2 and 3)
c) If  history of  moderate to severe hypersensitivity 
reaction 
• Consider performing the radiologic study without contrast 
media;
• Consider carrying out another type of  study;
• Postpone examination and:
• If  possible, refer the patient to an allergology consult 
in order to carry out an allergy study and establish a 
diagnosis and specific guidelines;
• According to the benefit, especially in the absence of  
an alternative, perform the imaging study with contrast 
media after “premedication” measures, according to the 
clinical situation - Corticoid + Anti-H1ns (Tables 2 and 
3).
• In this situation, consider using another active 
pharmacological principle of  contrast media, different 
from the one used in the previous study in which the 
hypersensitivity reaction occurred.
d) If  unstable asthma
In case the patient reports medical diagnosis of  asthma and 
presents with uncontrolled symptoms such as wheezing or 
bronchospasm, dyspnea and low effort tolerance:
• Consider performing the radiologic study without contrast 
media;
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• If  it is necessary to perform a radiologic study with 
CM administration, it must be postponed and have 
premedication programmed - corticoid - in this particular 
case it is important to perform the corticoid as an anti-
edematous (Tables 2 and 3).
e) If  history of  allergic reaction to other allergens
Follow the general indications specified above; this situation, 
by itself, does not require premedication.
8. Considerations for chemotoxic reactions
In order to minimize chemotoxic reactions in contrast 
medium in imaging, we must:
• Administer contrast in imaging study only if  there is a 
diagnosis benefit;
• Comply with the manufacturer’s handling and packaging 
instructions;
Table 2 - Pre-medication scheme according to risk factors
Pre-medication scheme
Previous history of  mild hypersensitivity reaction to contrast
Non-sedative anti-H1 2nd generation, orally (PO), 30 min before 
contrast administration (Table 3)
Previous history of  moderate to severe hypersensitivity reaction 
to contrast and examination cannot be postponed waiting for 
allergology appointment 
a) Adults and >12 year-old children
Prednisolone 50mg 13, 7 and 1 hour before PO or methylprednisolone 
32mg PO 12h and 2h before
PLUS
Non-sedative anti-H1 2nd generation PO 2 h prior to administration of  
contrast media
If  the patient cannot take oral medication choose for i.v pre-medication:
Ex: Hydrocortisone 200mg iv, 12h and 2h before contrast + Clemastine 
2mg 2h prior to administration of  contrast media
If  situations not programmed arise (patients in the ER):
Ex: Hydrocortisone 200mg and every 4h / 6h, until the radiologic study 
+ clemastine 2mg ev 1 hour before contrast.
b) ≥ 6 year-old children
Prednisolone 0.5 mg / kg PO 13, 7 and 1 h before or 
methylprednisolone 1 mg / kg PO 12 h and 2 h before
PLUS
Non-sedative anti-H1 2nd generation per os 2 h prior to administration 
of  contrast media
c) < 6 year-old children 
Ex: Betamethasone 0.03 mg / kg PO (in general it corresponds to 2 
drops per kg); 12 and 2 hours prior to administration of  contrast agent
PLUS
Non-sedative anti-H1 2nd generation PO 2 h prior to administration of  
contrast media
Unstable asthma
a) Adults and >12 years-old children
ex: prednisolone 0,5mg PO, 12h and 2h prior to contrast media 
administration.
b)  ≥ 6 years-old children 
ex: prednisolone 0,5mg/Kg (max 50mg), PO, 12h and 2h prior to 
contrast media administration.
c) < 6 years-old children
ex: betamethasone 0,03 mg/Kg PO (in general it corresponds to 2 
drops per Kg);  12h and 2h prior to contrast media administration.
Table 3 - Drugs that can be used as pre-medication
Name Formulation Children dose Adults 
dose
Antihistamine
Fexofenadine S,C 6-12 year-old: 30 mg 
>12 year-old:120-180 
mg 1x/day
120-180 mg
Cetirizine S,C 2 - 5 year-old: 2,5 mg 
6 - 11 year-old: 5 mg 
>12 year-old: 10 
mg/ day
10 mg
Loratadine S,C 2 - 11 anos:
≤ 30 kg: 5 mg
 > 30 kg: 10 mg 
>12 year-old, > 30 
kg: 10 mg
10 mg
Levocetirizine S,C 2 - 5 year-old: 1,25 
mg  
6 - 11 year-old: 5 mg 
> 12 year-old: 5 mg
5 mg
Desloratadine S,C 1 - 5 year-old: 1,25 
mg
6 - 11 year-old: 2,5 
mg
 > 12 year-old: 5 mg
5 mg
Ebastine S,C 2 - 5 year-old: 2,5 
mg/ day
 6 - 11 year-old: 5 
mg/ day 
>12 year-old: 10,0 
mg/ day
10-20 mg
Rupatadine S,C 2 - 11 year-old, 
10 - 25 kg: 2,5 mg 
≥ 25 kg: 5,0 mg
 > 12 year-old: 10 mg
10 mg
Bilastine C > 12 year-old: 20 
mg/ day
20 mg
Clemastine IM, IV 0,025 mg/Kg 2 mg
Corticoids
Prednisolone C, IV 0,5 mg/Kg PO
0,5 mg/Kg IV 
50 mg PO
50 mg IV
Metilprednisolone C, IV 1 mg/Kg PO
0,5 mg/Kg IV
32 mg PO
40 mg IV
Hydrocortisone IV 4 mg/Kg 200 mg
Betametasone S < 6 year-old:
Betamethasone 
0,03 mg/Kg PO 
(corresponding in 
general to 2 drops 
per Kg);
Deflazacort S,C < 6 year-old
1 mg /Kg(= 1 drop 
per Kg)
30 mg
S-Oral solution C-pill A-years PO-orally IV-intravenous
• In the case of  ICM, use iso-osmolar or low osmolarity 
contrast agents;
• Administer the minimum required dose/volume and 
the lowest flow rate possible, according to the clinical 
indication for the radiologic study;
• In the case of  ICM, to calculate volume and flow rate, the 
patient’s profile should also be taken into consideration, 
namely the presence of  cardiac pathology and the risk of  
water overload;
• Realize that anxiety, on its own, may be responsible for the 
occurence of  symptomatology identical to a true adverse 
reaction to contrast  media.
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9. Treatment of  non-renal acute adverse 
reactions to contrast media 
Any patient may develop, in any contrast-enhanced radiologic 
study, an acute adverse reaction, which should be promptly 
identified and treated. The patient should be guided in order 
to obtain a clinical or clinical-laboratory diagnosis, with 
implications in future radiologic studies.
The approach of  acute non-renal adverse reactions to 
contrast media is summarized in Figure 2.
There are a number of  universal measures that should be 
taken in all adverse reactions, including suspension of  
contrast administration, oxygen mask and monitoring:
• Elimination of  the triggering factor is essencial, meaning 
in this case the interruption of  contrast media infusion.
• Every patient should be placed in a comfortable position. 
Patients may prefer to be seated as it will ease their 
breathing. Dorsal decubitus, with elevation of  the lower 
limbs, is useful in hypotensive patients and when we think 
a vagal reaction is occurring. If  you feel that the patient 
is going to faint, he/she should not sit or stand up. The 
patient should be placed where he can easily take off  
the clothes in order to observe the progression of  skin 
lesions.
• Monitoring should always include at least respiratory rate, 
pulse oximetry, noninvasive blood pressure, and heart 
rate. 
• Oxygen must be placed by facial mask (high concentration 
mask) until the clinical situation is reevaluated.
In the event of  a mild reaction, only the universal measures 
should be taken and if  the symptoms are resolved, the patient’s 
surveillance must be kept in the radiology department for at 
least 30 minutes after the resolution of  the symptoms.
If  the suspicion is mild hypersensitivity reaction, a second 
generation non-sedative antihistamine drug may be used. 
In the event of  a moderate or severe reaction, the Medical 
Emergency Team (MET) must be immediately activated. If  
a hypersensitivity reaction is suspected, the on duty imaging 
physician should immediately administer Adrenalin IM (see 
Table 4). Until the arrival of  the MET, the professionals 
present must take the Basic Life Support measures 
appropriate to the clinical case.
9.1. Treatment of  chemotoxic reactions
The treatment of  these reactions is symptomatic and directed 
to the type of  reaction.
The majority of  reactions are mild; it is advisable to keep 
patient surveillance in the imaging department until 30 
minutes after the resolution of  symptoms.
If  the reaction is moderate or severe, the MET should 
be involved to do intensive treatment. In this case the 
surveillance should be extended until 8 hours, in an inpatient 
regime.
9.2. Treatment of  hypersensitivity reactions
9.2.1 Mild reactions
In the event of  a mild reaction, the universal measures, 
monitoring and surveillance described above must be taken. 
The indicated antihistaminic drugs are non-sedative (Table 
3) or in the case of  impossibility of  oral use, for example 
Figure 2 – Treatment of  hypersensitivity reactions to contrast media 
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Clemastine (the adult dose is 2 mg IV or IM, in children the 
correct dose is 0.025 mg / kg / IM or EV dose (up to a 
maximum of  2 mg) may be used, see table 4.
9.2.2 Moderate or severe
A moderate or severe AHRC is likely to be present when 
a patient develops sudden and unexpected illness (usually 
within minutes after administration of  contrast media), with 
rapidly progressing skin changes and potentially fatal airway 
and / or respiratory and / or circulatory system compromise.
The allergic reaction, being a specific and potentially fatal type 
of  adverse reaction, has a specific approach. This approach 
should be appropriate to the clinical severity of  the illness. 
This acting algorithm is based on the recommendations of  
the European Resuscitation Council (ERC).
ABCDE approach
The ABCDE methodology of  recognition and approach of  
any critical patient is the one that should be used in these 
situations.
Airway (A - airway) problems may correspond to edema 
of  the airways, and may be manifested as hoarseness or 
stridor and may progress to complete obstruction and 
cardio-respiratory arrest. Airway obstruction can occur 
quickly. The warning signs are edema of  the tongue and 
lips and hoarseness. Early involvement of  an airway expert 
(experienced anesthesiologist, intensivist) is mandatory in the 
treatment of  these patients. It is necessary to consider early 
tracheal intubation; any delay can make intubation extremely 
difficult. A surgical airway may be necessary if  tracheal 
intubation is not possible.
Breathing problems (B - breathing) can lead to dyspnea; 
wheezing, whistling; cyanosis; and confusion, frequently 
related to the presence of  bronchoconstriction and 
respiratory failure.
Circulatory problems (C - circulation) can range from 
hypotension to cardiac arrest. Circulatory problems (often 
referred to as anaphylactic shock) may be caused by direct 
myocardial depression or vasodilatation and increased 
capillary permeability.
Airway, Breathing, and Circulation problems referred above 
may alter the patient’s neurologic status (D - disability) due 
to decreased cerebral perfusion. There may be confusion, 
agitation and loss of  consciousness.
Adrenalin
It should be noted that if  there is suspicion of  moderate 
or severe hypersensitivity reaction, the drug of  choice is 
Adrenalin.
There are no absolute contraindications for treatment with 
intramuscular adrenalin in an anaphylaxis situation. Adverse 
effects are very rare when the correct doses are injected 
intramuscularly (IM). Subcutaneous or inhalation routes are 
not recommended.
In adults and children over 12 years of  age, administer an 
initial dose of  0.5 mg IM adrenalin (0.5 ml ampoule 1 mg / 
ml (1: 1000 adrenalin) = 0.5 mg = 500 mcg). Additional doses 
may be administered at intervals of  about 5 min, depending 
on the patient’s response, up to 3 administrations.
In children 6 to 12 years of  age the dose of  adrenalin is 0.3 
mg IM (0.3 ml ampoule 1 mg / ml (1: 1000 adrenaline) = 0.3 
mg = 300 mcg). In children less than 6 years of  age the dose 
of  adrenalin is 0.15 mg IM (0.15 ml ampoule 1 mg / ml (1: 
1000 adrenalin) = 0.15 mg = 150 mcg) (Table 4).
The best place for IM injection is the anterolateral zone of  the 
middle third of  the thigh. The needle must be long enough to 
ensure that adrenalin is injected into the muscle (21G green 
color, 4 cm, also known as an intramuscular needle).
IV adrenalin should only be administered by professionals 
experienced in the use and titration of  vasopressors in clinical 
practice (eg: anesthesiologists or intensivists). In patients 
with spontaneous circulation, intravenous adrenalin may 
cause potentially fatal hypertension, tachycardia, arrhythmias, 
and myocardial ischemia. Do not administer the 1: 1,000 
IV adrenalin solution without proper dilution (dilute 1 mg 
to 100 ml saline, you can use this dilution for bolus or for 
infusion). Titrate adrenalin IV in bolus of  20 to 50 mcg (2 to 
5 ml of  the proposed dilution) depending on the response. 
In children, do not titrate Adrenalin IV in bolus. If  repeated 
doses are required, establish IV infusion of  adrenalin using 
the existing tables (1 to 10 mcg / min is the usual dose 
which corresponds to 6 to 60 ml/h of  the previous dilution, 
titrating for the intended effect).
Adrenaline is the first-line vasopressor for the treatment of  
allergic reactions. Ponder other vasopressors and inotropes 
(noradrenaline, vasopressin, terlipressin) when the initial 
resuscitation with adrenalin and fluid is not successful. 
These drugs should only be used in specialized settings (eg: 
in intensive care units) where there is experience in their 
Table 4 - Drugs used in the treatment of  hypersensitivity reactions
ADRENALINE
(always administered IM - dose by weight - 0.01 mg / kg / dose)
Adult and >12 year-old child - administer an initial dose of  0.5 mg IM 
adrenalin (0.5 ml 1 ampoule 1 mg/ml = 0.5 mg = 500 mcg). Additional 
doses may be given at intervals of  about 5 min up to 3 doses.
6 to 12 year-old Children - administer an initial dose of  0.3 mg of  IM 
adrenalin (0.3 ml of  1 ampoule of  1 mg/ml = 0.3 mg = 300 mcg).
<6 year-old Children - administer an initial dose of  0.15 mg IM 
Adrenalin (0.15 ml 1 vial of  1 mg/ml = 0.15 mg = 150 mcg).
Adrenaline IV (only in case of  lack of  response to IM adrenaline 
and by a doctor with experience in its use)
(dilute one ampoule of  adrenaline (1mg/ml) up to 100ml of  saline 
solution - a concentration of  10ug / ml)
Adult: Bolus of  20 to 50 ug repeated every 1-2 minutes if  necessary; 
perfusion of  0.1-1 ug / kg / min, the same dilution can be used
Pediatrics: continuous infusion 0.1-1 ug / kg / min. Bolus IV not 
applicable.
FLUIDS
Adult - fast fluid bolus IV (500-1000 ml crystalloid), if  necessary 
administer additional doses.
Children - fluid bolus IV (20 ml/kg of  crystalloids).
OTHER DRUGS
Clemastine – 0,025 mg/kg/dose EV/IM (max - 2mg)
Hydrocortisone – adult - 200 mg; children - 4 mg /kg
Glucagon (resistance to adrenaline in beta-blocked patients) 
- bolus of  30 μg/kg / IV dose up to a maximum of  1 mg (may be 
repeated every 5 minutes)
Continuous perfusion 5-15ug/min (dilute one ampoule to 100ml of  
saline solution (10ug/ml))
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use. Glucagon may be useful in treating allergic reactions in 
patients taking beta-blockers.
Fluid therapy
Timely fluid therapy is one of  the determining factors to 
avoid and correct hypotension / distributive shock that may 
lead to cardiorespiratory arrest.
Rapid fluid bolus IV (500-1000 ml adult crystalloid) should 
be administered, monitoring the response and if  necessary 
administering additional doses. In children, a bolus of  
crystalloid fluids of  20 ml/ kg is recommended. In this 
context, Crystalloid are preferable as they are isotonic and 
glucose-free use (such as Poly® or Plasma-Lyte®).
Other drugs
The administration of  antihistamines, although reducing 
the symptoms is not life saving and should never delay the 
administration of  intramuscular adrenaline. The suggested 
antihistamine drug is Clemastine. The adult dose is 2 mg I.V 
or I.M. In the child the correct dose is 0.025mg/kg/dose 
I.M. or E.V (up to a maximum of  2mg).
There is little evidence to support the routine use of  H2 
antihistamines (eg ranitidine, cimetidine) for the treatment 
of  these conditions.
The administration of  corticosteroids is mainly for the 
prevention of  biphasic reactions (resurgence of  allergic 
reaction after 6 to 8 h) and it is neither life saving and should 
never delay the administration of  intramuscular adrenalin. 
There is little evidence as to the ideal dose of  corticosteroids; 
for example, the hydrocortisone suggested dose in adults is 
200 mg IV and in child 4 mg/kg IV slow.
Cardiorespiratory arrest
In the event of  a cardio-respiratory arrest, advanced life 
support measures should be immediately initiated, in 
accordance with the latest ERC guidelines.
10. Laboratory procedures
The diagnosis of  hypersensitivity reactions is clinical. There 
are several differential diagnoses that should be considered 
according to the severity of  the clinical manifestations, 
and excluded when necessary, never delaying the treatment 
intervention.
In all moderate to severe AHRC, a blood sample should be 
taken for quantification of  serum tryptase levels. When? as 
early as possible between 15 minutes to 6 hours after the 
onset of  symptoms.
In all moderate to severe AHRC, an allergology appointment 
is required. The increase of  serum triptase supports the 
diagnosis of  IgE-mediated hypersensitivity, but, if  normal, 
an anaphylactic reaction must not be excluded. In case of  
increase in the serum triptase value, a new sample should 
be taken after the resolution of  the symptoms, during the 
patient’s follow-up. Other complementary studies will be 
performed during follow-up.
11. Discharge and follow-up 
Patients with moderate to severe hypersensitivity reactions 
should be treated and observed for at least 8 hours in a 
facility that is capable of  treating these conditions. The exact 
incidence of  biphasic reactions that could warrant prolonged 
surveillance is unknown. There is no reliable way to predict 
who will undergo a biphasic reaction. Thus, it is important 
that discharge decisions are made for each individual patient 
by an experienced physician. There is no indication for 
outpatient maintenance if  all symptoms are resolved.
Before discharge, all patients should:
• Be informed about the nature of  the reaction and the 
need to continue clinical research. The patient should also 
be informed that he/she should avoid the contrast media 
until he/she goes to the allergology appointment.
• Get clear instructions to return to the hospital if  symptoms 
resurface.
• Be referred to a specialist in allergology.
11.1  Referral to an allergology medical appointment
The following patients should be referred to an allergology 
appointment:
• Patients with increased risk of  contrast media 
hypersensitivity reaction (suspicion of  moderate or severe 
reaction prior to contrast product). Referral by the imaging 
physician or the physician requesting the radiologic study.
• Patients who had a moderate or severe AHRC.
12. Records
12.1 Clinical records
Whenever an acute non-nephrotoxic adverse reaction occurs 
to the contrast media a clinical record should be made. 
This record should contain a description of  the clinical 
manifestations, therapy performed and time elapsed until 
resolution of  symptoms.
12.2 Pharmacovigilance registration
The adverse reaction should also be recorded on the 
“National Registry” (eg, INFARMED in Portugal).
13.  Alerts 
The insertion of  the hypersensitivity reaction information 
into the patient’s clinical / electronic process is fundamental 
to prevent future administrations and reactions.
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